Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Precision Biosciences Inc (NQ: DTIL ) 8.960 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Precision Biosciences Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 10, 2021 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies September 09, 2021 Precision BioSciences Inc (NASDAQ: DTIL) and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precision's PBGENE-... Via Benzinga The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization September 09, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... Via Benzinga Exposures COVID-19 The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight August 08, 2021 Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... Via Benzinga Exposures Product Safety Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline September 09, 2021 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies September 09, 2021 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications September 02, 2021 Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's... Via Benzinga Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment September 02, 2021 From Precision BioSciences, Inc. Via Business Wire The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab September 02, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... Via Benzinga Exposures COVID-19 Product Safety Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 August 25, 2021 From Precision BioSciences, Inc. Via Business Wire The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma August 12, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... Via Benzinga Exposures Product Safety Precision BioSciences: Q2 Earnings Insights August 12, 2021 Shares of Precision BioSciences (NASDAQ:DTIL) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 157.14% year... Via Benzinga Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update August 12, 2021 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021 August 05, 2021 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy July 01, 2021 Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin... Via Benzinga Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma July 01, 2021 From Precision BioSciences, Inc. Via Business Wire 60 Biggest Movers From Yesterday June 29, 2021 Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... Via Benzinga 44 Stocks Moving In Monday's Mid-Day Session June 28, 2021 Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... Via Benzinga Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial June 28, 2021 Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision... Via Benzinga Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma June 28, 2021 From Precision BioSciences, Inc. Via Business Wire 24 Stocks Moving in Monday's Pre-Market Session June 28, 2021 Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... Via Benzinga Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma June 04, 2021 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo June 01, 2021 From Precision BioSciences, Inc. Via Business Wire The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs May 27, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... Via Benzinga Exposures COVID-19 Precision BioSciences Appoints Alex Kelly as Chief Financial Officer May 27, 2021 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference May 26, 2021 From Precision BioSciences Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's After-Market Session May 20, 2021 Gainers Enveric Biosciences (NASDAQ:ENVB)... Via Benzinga Precision BioSciences' CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial May 20, 2021 Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate... Via Benzinga The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks May 20, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:... Via Benzinga Exposures COVID-19 Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting May 19, 2021 From Precision BioSciences, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.